Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
About 10-20% of all individuals with breast cancer have a so-called triple-negative tumor (TNBC). This type of breast cancer has a particularly unfavorable course and a higher mortality rate compared to other forms of breast cancer. Research studies show that it is important for individuals with TNBC to achieve a so-called pathologic complete response (pCR) to treatment. In the phase II study SAKK 66/22, it is being investigated whether the administration of the drug INT230-6 before surgery for breast cancer can increase the rate of pCR in the tumor and affected lymph nodes. The tolerability of INT230-6 as well as other factors such as response to treatment and the possibility of breast-conserving surgery are also being examined.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Dobrowolna zgoda na uczestnictwo w badaniu przed jego rozpoczęciem.
- •Nowodiagnozowany, nieleczony wcześniej zaawansowany rak piersi bez przerzutów (typ TNBC).
- •Stadium zaawansowania: guz 1,5-2 cm z rozroście w węzłach chłonnych lub guz większy (2-4 cm) z rozroście węzłów lub bez.
- •Możliwość wystąpienia kilku ognisk guza; przy wielu ogniskach wszystkie muszą być typu TNBC.
- •Guz w piersi mierzalny (co najmniej 1,5 cm średnicy), widoczny w badaniu ultrasonograficznym i możliwy do zainjektowania.
- •Wiek 18 lat lub więcej.
- •Dobry ogólny stan zdrowia (skala ECOG 0-1).
- •Prawidłowe wyniki badań krwi: liczba neutrofili, płytek krwi, hemoglobiny, wątroby, nerek i krzepnięcia krwi.
✗ Disqualifies
- •Zapalny rak piersi.
- •Stosunek wielkości guza do wielkości piersi niekorzystny dla zachowania piersi.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- April 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (9)
Tumor Zentrum Aarau
Aarau, Switzerland
St. Claraspital
Basel, Switzerland
EOC - IOSI Ospedale regionale Bellinzona e valli - San Giovanni
Bellinzona, Switzerland
Kantonsspital Graubünden
Chur, Switzerland
Kantonsspital Baselland
Liestal, Switzerland
HOCH Health Ostschweiz
Sankt Gallen, Switzerland
TBZO - Tumor- & Brustzentrum Ostschweiz
Sankt Gallen, Switzerland
Kantonsspital Winterthur
Winterthur, Switzerland
Universitätsspital Zürich - Klinik für Gynäkologie
Zurich, Switzerland
Trial contact
Jana Musilova, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.